FMP
NASDAQ
0.934 USD
0.0491 (5.26%)
Mr. Howard W. Robin
Healthcare
Biotechnology
https://www.nektar.com
NASDAQ
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the t...
0000906709
US6402681083
640268108
455 Mission Bay Boulevard Sout...
415 482 5300
US
137
May 3, 1994
0000906709
NASDAQ
Biotechnology
Healthcare
640268108
US6402681083
US
0.93
0.86
1.62M
171.54M
-
0.41-1.12
3.5
-
-
-
-
-0.64
-
https://www.nektar.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.